Drawing for REAXIUM

USPTO serial 87399196

REAXIUM

Reviewed by CopyMark Law Group

Reg. 5323139Status 702Renewal
Filing date
Status date
Registration date
Oct 31, 2017
Examiner
SINGH, TEJBIR
Law office
TMEG LAW OFFICE 106

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with REAXIUM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*

Plus Government fees of $1,300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Albert Bordas, Esq

Albert Bordas, Esq Albert Bordas, P.A.5975 Sunset DriveSuite 705Miami, FL 33143

Goods and services

ClassDescriptionStatusFirst use
009Mobile biometric scanner and location monitoring transponders; Mobile biometric scanner and location monitoring transponders for use on school buses; Downloadable mobile software application for use by parents to securely geo-locate school buses and students in real timeACTIVEJul 20, 2016
042Software as a service featuring software for securely monitoring school bus routes and geo-locating school buses and students in real time; Platform-as-a-service featuring software platforms enabling secure monitoring of school bus and student rider locations in real timeACTIVEJul 20, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 14, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
May 14, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
May 14, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 9, 2023E815TEAS SECTION 8 & 15 RECEIVED
Oct 31, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 3, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 3, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 31, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 19, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 15, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 15, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 26, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 7, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 3, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jul 3, 2017XAECEXAMINER'S AMENDMENT ENTERED
Jul 3, 2017ALIEASSIGNED TO LIE
Jul 3, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 3, 2017GNEAEXAMINERS AMENDMENT E-MAILED
Jul 3, 2017CNEAEXAMINERS AMENDMENT -WRITTEN
Jun 27, 2017DOCKASSIGNED TO EXAMINER
Apr 11, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 8, 2017NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance